Differential immunoreactivity of p16 in leiomyosarcomas and leiomyoma variants

International Journal of Gynecological Pathology

Volumn 27, Issue 1, 2008, Pages 68-73

  Gannon, Brian R ^a   Manduch, Marosh ^a   Childs, Timothy J ^a,b  

^a QUEEN S UNIVERSITY   (Canada)

^b KINGSTON GENERAL HOSPITAL   (Canada)

Author keywords

Immunohistochemistry; Leiomyoma; Leiomyosarcoma; p16; Uterus

Indexed keywords

CALDESMON; CYTOKERATIN 18; PROTEIN P16; SOMATOMEDIN C; CALMODULIN BINDING PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; SOMATOMEDIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LEIOMYOMA; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; TISSUE MICROARRAY; BIOSYNTHESIS; DIFFERENTIAL DIAGNOSIS; GENE EXPRESSION; GENE EXPRESSION PROFILING; METABOLISM; MIDDLE AGED; PATHOLOGY; UTERUS CANCER;

ADULT; AGED; CALMODULIN-BINDING PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-18; LEIOMYOMA; LEIOMYOSARCOMA; MIDDLE AGED; SOMATOMEDINS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS;

EID: 39349107670     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/pgp.0b013e3180ca954f     Document Type: Article

References (15)

1. Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol 1994;18:535-58.
2. Prayson RA, Hart WR. Mitotically active leiomyomas of the uterus. Am J Clin Pathol 1992;97:14-20.
3. Watanabe K, Suzuki T. Uterine leiomyoma versus leiomyosarcoma: a new attempt at differential diagnosis based on their cellular characteristics. Histopathology 2006;48:563-8.
4. Lee EJ, Kong G, Lee SH, et al. Profiling of differentially expressed genes in human uterine leiomyomas. Int J Gynecol Cancer 2005;15:146-54.
5. Quade BJ, Wang TY, Sornberger K, et al. Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling. Genes Chromosomes Cancer 2004;40:97-108.
6. Skubitz KM, Skubitz AP. Differential gene expression in leiomyosarcoma. Cancer 2003;98:1029-38.
7. Skubitz KM, Skubitz AP. Differential gene expression in uterine leiomyoma. J Lab Clin Med 2003;141:297-308.
8. Wang H, Mahadevappa M, Yamamoto K, et al. Distinctive proliferative phase differences in gene expression in human myometrium and leiomyomata. Fertil Steril 2003;80:266-76.
9. Tsibris JC, Segars J, Coppola D, et al. Insights from gene arrays on the development and growth regulation of uterine leiomyomata. Fertil Steril 2002;78:114-21.
10. Zhai YL, Nikaido T, Orii A, et al. Frequent occurrence of loss of heterozygosity among tumor suppressor genes in uterine leiomyosarcoma. Gynecol Oncol 1999;75:453-9.
11. Bodner-Adler B, Bodner K, Czerwenka K, et al. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis. Gynecol Oncol 2005;96:62-6.
12. Zaloudek C, Hendrickson MR. Mesenchymal tumors of the uterus. In: Kurman RJ, ed. Blaustein's Pathology of the Female Genital Tract. New York, NY: Springer-Verlag; 2002:583.
13. Serrano M. The tumor suppressor protein p16INK4a. Exp Cell Res 1997;237:7-13.
14. Santos M, Montagut C, Mellado B, et al. Immunohistochemical staining for p16 and p53 in premalignant and malignant epithelial lesions of the vulva. Int J Gynecol Pathol 2004;23:206-14.
15. Tringler B, Gup CJ, Singh M, et al. Evaluation of p16INK4a and pRb expression in cervical squamous and glandular neoplasia. Hum Pathol 2004;35:689-96.